These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19225777)

  • 1. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.
    Delluc S; Hachem P; Rusakiewicz S; Gaston A; Marchiol-Fournigault C; Tourneur L; Babchia N; Fradelizi D; Regnault A; Sang KH; Chiocchia G; Buzyn A
    Cancer Immunol Immunother; 2009 Oct; 58(10):1669-77. PubMed ID: 19225777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
    Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
    Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.
    Delluc S; Tourneur L; Fradelizi D; Rubio MT; Marchiol-Fournigault C; Chiocchia G; Buzyn A
    Cancer Immunol Immunother; 2007 Jan; 56(1):1-12. PubMed ID: 16676183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
    Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
    Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
    Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW
    Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
    Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells.
    Prasad SJ; Farrand KJ; Matthews SA; Chang JH; McHugh RS; Ronchese F
    J Immunol; 2005 Jan; 174(1):90-8. PubMed ID: 15611231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.
    Vogt V; Schick J; Ansprenger C; Braeu M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
    J Immunother; 2014; 37(6):331-47. PubMed ID: 24911794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice.
    Pawlowska AB; Hashino S; McKenna H; Weigel BJ; Taylor PA; Blazar BR
    Blood; 2001 Mar; 97(5):1474-82. PubMed ID: 11222396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
    Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.
    Tan C; Reddy V; Dannull J; Ding E; Nair SK; Tyler DS; Pruitt SK; Lee WT
    J Transl Med; 2013 Jun; 11():148. PubMed ID: 23768240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
    Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
    Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Immunobiology; 2005; 210(2-4):249-57. PubMed ID: 16164032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.